Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Phase 1

Withdrawn

Conditions: Melanoma

Interventions: Drug: rAd.CD40L
Drug: Pembrolizumab

First Posted Date: 2016-03-24

Last Posted Date: 2017-11-24

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02719015

Effects of Social Networking on Chronic Disease Management in Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis
Chronic Disease Management

Interventions: Behavioral: Questionnaires
Behavioral: Facebook
Behavioral: Educational Website
Behavioral: Phone Interview

First Posted Date: 2016-03-23

Last Posted Date: 2023-06-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 210

Registration Number: NCT02717403

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases

Not Applicable

Terminated

Conditions: Cancer Survivor
Metastatic Malignant Neoplasm in the Bone
Bone Metastases

Interventions: Other: Monitoring Device
Other: Physical Activity Measurement
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Standard Follow-Up Care
Other: Survey Administration

First Posted Date: 2016-03-22

Last Posted Date: 2022-10-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT02715856

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

Phase 2

Active, not recruiting

Conditions: Malignant Digestive System Neoplasm
Metastatic Kidney Carcinoma
Metastatic Head and Neck Carcinoma
Metastatic Malignant Neoplasm of Unknown Primary
Solid Neoplasm
Spinal Cord Compression
Stage IV Breast Cancer AJCC v6 and v7
Metastatic Malignant Neoplasm in the Spine
Metastatic Melanoma
Sarcoma

Interventions: Procedure: Computed Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Radiosurgery
Procedure: Thermal Ablation Therapy

First Posted Date: 2016-03-18

Last Posted Date: 2025-04-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT02713269

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

Phase 2

Recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Metastatic Malignant Solid Neoplasm

Interventions: Radiation: External Beam Radiation Therapy
Other: Laboratory Biomarker Analysis
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2016-03-16

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 230

Registration Number: NCT02710253

Locations: 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson West Houston, Houston, Texas, United States

and more 2 locations

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Phase 1

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: APX005M
Drug: Pembrolizumab

First Posted Date: 2016-03-11

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT02706353

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Stage IV Prostate Adenocarcinoma AJCC v7
Castration Levels of Testosterone
PSA Progression

Interventions: Drug: Abiraterone Acetate
Drug: Apalutamide
Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Drug: Cabazitaxel
Drug: Carboplatin
Drug: Prednisone

First Posted Date: 2016-03-09

Last Posted Date: 2025-05-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 196

Registration Number: NCT02703623

Locations: 🇺🇸
MD Anderson in Katy, Houston, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson in Sugar Land, Sugar Land, Texas, United States

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Phase 1

Withdrawn

Conditions: Lymphoma

Interventions: Drug: Busulfan
Drug: Caphosol
Drug: Glutamine
Drug: Pyridoxine
Drug: Belinostat
Drug: Azacitidine
Drug: Gemcitabine
Drug: Melphalan
Procedure: Stem Cell Transplant

First Posted Date: 2016-03-08

Last Posted Date: 2016-05-04

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02701673

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

Not Applicable

Active, not recruiting

Conditions: Tobacco Use Disorder
Cigarette Smoker

Interventions: Behavioral: Behavioral Intervention
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration
Drug: Nicotine Patch
Behavioral: Smoking Cessation Intervention

First Posted Date: 2016-03-03

Last Posted Date: 2025-04-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 85

Registration Number: NCT02697227

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

Not Applicable

Active, not recruiting

Conditions: Recurrent Brain Neoplasm

Interventions: Other: Quality-of-Life Assessment
Biological: Bevacizumab
Radiation: Radiation Therapy

First Posted Date: 2016-03-03

Last Posted Date: 2025-05-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT02698254

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy